$TEVA

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.

Original reporting
Published Jul 29, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wed: Teva jumps but TASE continues to lose ground — source image
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

Teva’s raised revenue guidance is the only explicitly described company-specific fundamental driver, making it the primary tradable signal. Other large movers are reported without disclosed catalysts, reducing conviction.

02

Market read

For traders, the actionable edge is Teva’s guidance-driven repricing amid a broadly weaker TASE tape.

03

What to watch

The article does not provide the magnitude or specifics of Teva’s raised guidance, nor does it explain the catalysts for other movers, so follow-through risk is elevated.

Relevance 7/10Novelty 6/10Timing: same-day reaction after Teva’s Q2 results and raised revenue guidance

Background

The piece is a Tel Aviv market wrap with index declines, sector weakness, and a standout Teva earnings and guidance catalyst.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva led the Tel Aviv 35 Index, up 10.17%, after reporting Q2 results and raising revenue guidance.

Expected impact

Bullish bias for the next few sessions as traders digest the raised revenue guidance; watch for follow-through vs mean reversion.

Evidence & confidence

The article attributes the 10.17% jump directly to Q2 results and raised revenue guidance, which is a concrete catalyst for repricing.

$NICEBullishLow confidence
Context

Nice rose 5.79% on the day, contributing to the Tel Aviv 35 Index’s strongest movers alongside Teva.

Expected impact

Short-term positive drift is possible, but conviction is limited without a disclosed fundamental driver.

Evidence & confidence

No earnings, guidance, deal, or other primary event is described for Nice in the text.

$ENLTBearishLow confidence
Context

Enlight Renewable Energy fell 4.79%, the biggest decliner on the Tel Aviv 35 Index, during a broadly weaker market.

Expected impact

Near-term downside pressure could persist if selling is momentum-driven, but fundamentals are unclear from this text.

Evidence & confidence

The body lists the percentage move without any specific news catalyst for ENLT.

$ESLTBearishLow confidence
Context

Elbit Systems fell 4.30% on the day, among the notable decliners on the Tel Aviv 35 Index.

Expected impact

Potential for continued volatility, but directional conviction is low without a catalyst.

Evidence & confidence

The text only states the percentage move and does not mention earnings, guidance, contracts, or other events for Elbit.

$NVMIBearishLow confidence
Context

Nova Ltd. dropped 3.91% on the day, listed as one of the notable losers on the Tel Aviv 35 Index.

Expected impact

Watch for follow-through only if broader risk-off persists; company-specific signal is weak.

Evidence & confidence

No discrete NVMI-specific catalyst is provided beyond the decline.

Market effects

Technology index down 2% and banking down 1.5% suggest risk-off pressure, which can amplify dispersion around idiosyncratic earnings/guidance winners like Teva.

Tel Aviv indices broadly lower, implying traders may be reallocating within Israel equities rather than adding net risk.

Limited direct global linkage in the text; the main global read-through is Teva’s guidance affecting sentiment toward pharma earnings season.

Counterpoint

Teva’s +10% move may partially reflect positioning and could mean higher near-term volatility rather than a durable trend if the guidance details are already anticipated.

Key entities

  • Teva Pharmaceutical Industries Ltd.

    Reported Q2 results and raised revenue guidance, driving a +10.17% jump and highest turnover on the Tel Aviv 35 Index.

  • Nice

    Reported as up 5.79% on the day, but no specific catalyst is described in the text.

  • Enlight Renewable Energy

    Reported as down 4.79%, with no catalyst provided in the text.

Related articles

$BTAIHighAI 9/10

BioXcel Therapeutics Agrees To Teva Asset Sale

BioXcel Therapeutics (BTAI) agreed to sell its assets to Teva Pharmaceuticals and filed for Chapter 11 bankruptcy. The deal includes IGALMI and BXCL501. The company secured $19M in financing and plans to seek higher bids. IGALMI remains available, and BXCL501's FDA decision is due November 14. BTAI stock is down 46.30% pre-market.

$TEVAMed

Teva share price hits nearly 10-year high

Teva Pharmaceutical (TEVA) reached a nearly 10-year high, with shares up 1.44% on Friday, giving a $43.51B market cap. The company reported strong Q2 results, raised annual revenue guidance, and received debt rating upgrades from Moody's and Fitch. The FDA accepted its Ecopipam drug application. Analysts have an average price target of $42.38, a 12.3% premium to current levels.

$TEVAMedAI 8/10

Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceuticals (TEVA) announced the FDA granted Priority Review to its New Drug Application for ecopipam, a potential treatment for pediatric Tourette syndrome. If approved, ecopipam could be the first new treatment in over a decade and the first new mechanism in over 50 years, potentially boosting Teva's neuroscience portfolio. The company projects $18.1 billion revenue and $2.7 billion earnings by 2029, with analysts offering varying outlooks on its growth prospects.

$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.